Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

KOL Insight: Renal Cell Carcinoma [2020]

Product Code:
596201727
Publication Date:
September 2020
Format:
PDF + PPTX
Licence Type:
Multi-user licence

Therapy Trends KOL Insight: Renal Cell Carcinoma [2020]

Combination immunotherapies have revolutionised the treatment of advanced RCC but how do KOLs assess the clinical value of Merck & Co./Pfizer's Keytruda/Inlyta and Bristol Myers Squibb's Opdivo/Yervoy? And what has sparked KOLs' interest in Merck & Co's pipeline HIF-2α inhibitor MK-6482, as both monotherapy and in combination with Exelixis/Ipsen's Cabometyx? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • Has AstraZeneca arrived too late in the game with its Imfinzi/ tremelimumab combination and where do expert see value going forward?
  • What factor are limiting uptake of Merck Group/Pfizer's Bavencio/Inlyta combination and what are the alternative approaches KOLs suggest?
  • How do experts suggest Xynomic Pharmaceuticals' could differentiate combination oral HDAC inhibitor abexinostat with Votrient in RCC patients?
  • What are Roche's options following disappointing IMmotion151 trial results for combination Avastin/Tecentriq?
  • How do KOLs view the potential of newer drug classes, such as HIF-2α inhibitors and HDAC inhibitors?

Examples of Therapies Covered

Bavencio Keytruda
Opdivo Imfinzi
Tecentriq Cabometyx
Fotivda Inlyta
Sutent Votrient

Partial List of Participating KOLs

  • Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, Georgetown University School of Medicine, Washington, DC
  • Associate Professor of Oncology, Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY
  • Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Professor of Oncology and Chief of the Oncology Clinical and Translational Research Unit at Georges Pompidou Hospital, Paris, France
  • Professor of Medicine, Head of the SS Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Email*
Job Title*
Phone*
Company Name *
Country Name *
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved